In:
American Journal of Veterinary Research, American Veterinary Medical Association (AVMA), Vol. 63, No. 4 ( 2002-04-01), p. 506-512
Abstract:
Objective —To determine the efficacy of trilostane, a
3β-hydroxysteroid dehydrogenase inhibitor, in dogs with pituitary-dependent hyperadrenocorticism (PDH). Animals —11 dogs with PDH. Procedure —The initial dose of trilostane was 30 mg,
PO, q 24 h for dogs that weighed 〈 5 kg and 60 mg,
PO, q 24 h for dogs that weighed ≥ 5 kg. A CBC count, serum biochemical analyses, urinalysis, ACTH
stimulation test, and ultrasonographic evaluation of the adrenal glands were performed in each dog 1, 3
to 4, 6 to 7, 12 to 16, and 24 to 28 weeks after initiation of treatment. Results —All dogs responded well to treatment. All had
reductions in polyuria-polydipsia and panting and an increase in activity. Polyphagia decreased in 9 of 10
dogs, and 9 of 11 dogs had improvement of coat quality and skin condition. Concentration of cortisol after
ACTH stimulation significantly decreased by 1 week after initiation of treatment. After treatment for 6
months, clinical signs resolved in 9 dogs. In the other 2 dogs, marked clinical improvement was reported for 1
dog, and moderate improvement was reported in the other dog. Ultrasonographically, there was a considerable
change in the parenchyma and an increase in size of the adrenal glands. Adverse effects consisted of 1
dog with transient lethargy and 1 dog with anorexia. Conclusions and Clinical Relevance —Trilostane is
an efficacious and safe medication for treatment of dogs with PDH. Additional studies in a larger group of
dogs and characterization of progressive changes in adrenal glands are needed. ( Am J Vet Res 2002;63:506–512).
Type of Medium:
Online Resource
ISSN:
0002-9645
DOI:
10.2460/ajvr.2002.63.506
Language:
Unknown
Publisher:
American Veterinary Medical Association (AVMA)
Publication Date:
2002
detail.hit.zdb_id:
2056942-7
SSG:
22
Bookmarklink